February 14, 2019 2019-02-15 00:00:12Opdivo (nivolumab) Plus Yervoy (ipilimumab) Shows Response in Pre-Treated Patients with Metastatic Castration-Resistant Prostate CancerBristol-Myers Squibb Companyipilimumab L01XC11 , nivolumab L01XC17 OPDIVO , YERVOY Hormone resistant malignancy statusMalignant neoplasm of prostateClinical trials, phase 2
February 14, 2019 2019-02-14 08:04:19Janssen Announces Preliminary Results from Phase 2 GALAHAD Study in Adults with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Pathway Defects (DRD)Janssen Research & Development, LLCniraparib L01XX54 Hormone resistant malignancy statusMalignant neoplasm of prostateClinical trials, phase 2
February 14, 2019 2019-02-14 06:00:43Merck Increases Focus on Advanced Prostate Cancer, Expanding Immuno-Oncology Program with Three New Phase 3 TrialsMerck Sharp & Dohme Corp.docetaxel L01CD02 , enzalutamide L02BB04 , prednisone A07EA03 KEYTRUDA , Lynparza Hormone resistant malignancy statusMalignant neoplasm of prostateClinical trials, phase 3
February 11, 2019 2019-02-11 12:59:14Study finds upsurge in ‘active surveillance’ for low-risk prostate cancerDana-Farber Cancer InstituteMalignant neoplasm of prostate
January 30, 2019 2019-01-30 13:02:50Janssen Announces ERLEADA® (apalutamide) Phase 3 TITAN Study Unblinded as Dual Primary Endpoints Achieved in Clinical Program Evaluating Treatment of Patients with Metastatic Castration-Sensitive Prostate CancerJohnson & Johnsonapalutamide L02BB05 ERLEADA Hormone sensitive malignancy statusMalignant neoplasm of prostateClinical trials, phase 3
January 30, 2019 2019-01-30 09:02:40Janssen Announces ERLEADA® (apalutamide) Phase 3 TITAN Study Unblinded as Dual Primary Endpoints Achieved in Clinical Program Evaluating Treatment of Patients with Metastatic Castration-Sensitive Prostate CancerJanssen Research & Development, LLCapalutamide L02BB05 ERLEADA Hormone sensitive malignancy statusMalignant neoplasm of prostateClinical trials, phase 3
January 23, 2019 2019-01-23 20:33:47The Final Verdict on FinasterideSWOG Cancer Research Networkfinasteride G04CB01 Malignant neoplasm of prostate
January 23, 2019 2019-01-23 10:03:57Trovagene Announces New Patent Issued for Combination of Onvansertib with Anti-Androgen Drugs to Treat Non-Metastatic and Metastatic Prostate CancerTrovagene, Inc.onvansertib L01X Xtandi , Zytiga , ERLEADA Hormone resistant malignancy statusMalignant neoplasm of prostate
January 15, 2019 2019-01-16 23:06:45Janssen announces European Commission approval of ERLEADA® (apalutamide) for non-metastatic castration-resistant prostate cancer patients who are at high risk of developing metastatic diseaseJohnson & Johnsonapalutamide L02BB05 ERLEADA Hormone resistant malignancy statusMalignant neoplasm of prostate
January 09, 2019 2019-01-25 00:39:59Telix Pharmaceuticals Limited announced a strategy update for the TLX591 (prostate therapy) programTelix Pharmaceuticals LimitedTLX591 L01XC Malignant neoplasm of prostate
January 04, 2019 2019-01-21 01:06:55Arvinas Receives Authorization to Proceed for its IND Application for PROTAC™ Therapy to Treat Patients with Metastatic Castration-Resistant Prostate CancerArvinas, Inc.ARV-110 L01X Hormone resistant malignancy statusMalignant neoplasm of prostate
January 03, 2019 2019-01-03 02:06:32Progenics and Curium Announce European Collaboration for Prostate Cancer Imaging Agent PyL™Progenics Pharmaceuticals, Inc.PyL V09I Malignant neoplasm of prostateCollaboration
January 02, 2019 2019-01-11 21:15:08Harpoon Therapeutics Announces Preliminary Safety and Pharmacology Data from its HPN424 Phase 1 Trial in Prostate CancerHarpoon TherapeuticsHPN424 L Malignant neoplasm of prostate